Sign In
Buy KURA
$8.66
-0.315 (-3.51%)
At Close: Jun 03, 2026
Kura Oncology: Advanced Precision Medicine Opportunity Excites, But Not Without Risks
01:45pm, Thursday, 10'th Dec 2020
Kura Oncology looks an attractive opportunity in the Precision Medicine / Targeted Therapies sector.
Kura Oncology to Participate in the JMP Securities Hematology Summit
07:30am, Thursday, 10'th Dec 2020
SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock
08:22pm, Tuesday, 08'th Dec 2020
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology Announces Commencement of Public Offering of Common Stock
04:01pm, Monday, 07'th Dec 2020
SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting
12:30pm, Saturday, 05'th Dec 2020
– Evidence of biologic activity observed in each dose-escalation cohort treated to date –
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2020 Results - Earnings Call Transcript
01:21pm, Saturday, 07'th Nov 2020
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2020 Results - Earnings Call Transcript
Kura Oncology to Participate in Three Upcoming Investor Conferences
07:30am, Wednesday, 04'th Nov 2020
SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology to Report Third Quarter 2020 Financial Results
07:30am, Thursday, 29'th Oct 2020
SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cance
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
10X Genomics Inc (NASDAQ: TXG)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Avenue Therapeutics Inc (NASDAQ: ATXI)...
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)
Catalent Inc (NYSE: CTLT)
CureVac N.V. (NASDAQ: CVAC) (follow-on buying after a 250% advance on its debut Friday...
Looking Under The Covers At Kura Oncology
12:53pm, Thursday, 13'th Aug 2020
Today, we take an in-depth look at Kura Oncology. The company is advancing a couple of late-stage pipeline assets.
Kura Oncology Reports Second Quarter 2020 Financial Results
08:05pm, Thursday, 06'th Aug 2020
– Anticipate preliminary data presentation of menin inhibitor program, KO-539, at ASH – – Continued progress in registration-directed trial of tipifarnib in HRAS mutant HNSCC –– Opportunity
Kura Oncology to Present at Wedbush PacGrow Healthcare Virtual Conference
11:30am, Tuesday, 04'th Aug 2020
SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology to Report Second Quarter 2020 Financial Results
11:30am, Thursday, 30'th Jul 2020
SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cance
How Many Kura Oncology, Inc. (NASDAQ:KURA) Shares Do Institutions Own?
02:23pm, Wednesday, 29'th Jul 2020
A look at the shareholders of Kura Oncology, Inc. (NASDAQ:KURA) can tell us which group is most powerful. Institutions...
